# Shire SCT: Lisdexamfetamine Treatment for ADHD and SCT

> **NCT02635035** · PHASE2 · COMPLETED · sponsor: **NYU Langone Health** · enrollment: 38 (actual)

## Conditions studied

- Attention Deficit Disorder
- Attention Deficit Hyperactivity Disorder

## Interventions

- **DRUG:** Lisdexamfetamine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02635035
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11
- **Primary completion:** 2019-01-09
- **Final completion:** 2019-01-09
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2021-11-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02635035

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02635035, "Shire SCT: Lisdexamfetamine Treatment for ADHD and SCT". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02635035. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*